glp-1 for autoimmune disease The anti-inflammatory and immunological properties of Receptor Agonists Microdosing GLP-1 for autoimmune conditions:

It also points to the need for better strategies to make these treatments more accessible and available to those who need them. Prior to this research, a small study of 106 postmenopausal women published in 2024 in the medical journal Menopause found that those who were on both MHT and the GLP-1 drug semaglutide had lost about 16 percent of their total body weight after a year, compared to 12 percent for women on a GLP-1 alone

Leaner patients with maintenance or performance goals tend to do better on CJC-1295/Ipamorelin

Some patients experience persistent mild constipation

The causes of this are multifactorial and can include genetic abnormalities, medications (chemotherapy, testosterone, radiation), infections, and idiopathic causes